HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: clinchem.2004.038059v1 50/10/1804    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (10) Citing Articles via Google Scholar Google Scholar Articles by Palomaki, G. E. Articles by Pandian, R. Search for Related Content PubMed PubMed Citation Articles by Palomaki, G. E. Articles by Pandian, R. Related Collections General Clinical Chemistry Proteomics and Protein Markers

Maternal Serum Invasive Trophoblast Antigen (Hyperglycosylated hCG) as a Screening Marker for Down Syndrome during the Second Trimester

¹ Foundation for Blood Research, Scarborough, ME.
² Quest Diagnostics, Nichols Institute, San Juan Capistrano, CA.

^aAddress correspondence to this author at: Foundation for Blood Research, PO Box 190, Scarborough, ME 04070-00190. Fax 207-885-0807; e-mail palomaki{at}fbr.org.

Background: Approximately two million pregnancies in the United States are screened for Down syndrome annually by use of second-trimester maternal serum markers. At present, a combination of four markers can identify 75% of affected pregnancies when 5% of screened women are classified as candidates for amniocentesis. Although not currently included in screening panels, invasive trophoblast antigen (ITA) is a promising screening marker in serum or urine in both the second and first trimesters. This study aims at better defining the screening performance of serum ITA in the second trimester.

Methods: In an earlier study, serum samples from an unbiased sampling of 45 Down syndrome (cases) and 238 unaffected (control) pregnancies between 14 and 20 weeks of gestation were collected from various centers in the United States. Samples were aliquoted and stored at –20 °C for 8 years. We measured ITA in these samples and determined the screening performance both univariately and in combination with other screening markers.

Results: The median ITA in Down syndrome pregnancies was >3.00 multiples of the median, higher than that found for human chorionic gonadotropin (hCG) or free ß-hCG. At a 5% false-positive rate, ITA univariately detected 38% and 40% of Down syndrome pregnancies, respectively, when assigned by date of last menstrual period or ultrasound date. Modeling yielded rates of 45% and 48%. ITA correlated strongly with hCG and free ß-hCG. When substituted for either of these in a multiple marker panel, ITA performed comparably.

Conclusions: This study indicates that serum ITA is an effective marker for Down syndrome. It is highly correlated with both hCG and free ß-hCG and could replace either of them in a multiple marker panel.

The following articles in journals at HighWire Press have cited this article:

				G. E. Palomaki, G. J. Knight, L. M. Neveux, R. Pandian, and J. E. Haddow Maternal Serum Invasive Trophoblast Antigen and First-Trimester Down Syndrome Screening Clin. Chem., August 1, 2005; 51(8): 1499 - 1504. [Abstract] [Full Text] [PDF]